Photo by nci from unsplash
single-agent chelation therapies. Br J Haematol. 2011;15(5):654-656. 4. Elalfy M, Adly AM, Wali Y, Tony S, Samir A, Elhenawy YI. Efficacy and safety of a novel combination of two oral… Click to show full abstract
single-agent chelation therapies. Br J Haematol. 2011;15(5):654-656. 4. Elalfy M, Adly AM, Wali Y, Tony S, Samir A, Elhenawy YI. Efficacy and safety of a novel combination of two oral chelators deferasirox/deferiprone over deferoxamine/deferiprone in severely iron-overloaded young beta thalassemia major patients. Eur J Haematol. 2015;95(5):411-420. 5. Balocco M, Carrara P, Pinto V, Forni GL. Daily alternating deferasirox and deferiprone therapy for “hard-to-chelate” β-thalassemia major patients. Am J Hematol. 2010;85(6):460-461. 6. Pinto VM, Bacigalupo L, Gianesin B, et al. Lack of correlation between heart, liver and pancreas MRI-R2*: results from long-term follow-up in a cohort of adult B-thalassemia major patients. Am J Hematol. 2018;93(3):E79-E82.
Journal Title: American Journal of Hematology
Year Published: 2018
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!